Fritextsökning
Artiklar per år
Innehållstyper
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Fokus Patient blir internationellt
I oktober arrangerar Fokus Patient konferenser i dagarna tre. Fokus ligger i år på internationella samarbeten.
-
Konferens om läkemedelsformuleringar samlar branschen i Köpenhamn
Idag pågår den tionde upplagan av New Updates in Drug Formulation & Bioavailability 2022 i Köpenhamn.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
Skånskt medtech-bolag får ny storägare
Fåhraeus Startup & Growth Fund går in som en av huvudägarna i medtech-bolaget Airsonett.
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which
-
Ny styrelseordförande till Epista Life Science
Per Kogut blir ny styrelseordförande och Ronny Roos lämnar därmed ordförandeposten, men stannar kvar i styrelsen.
-
Michael Treschow och Jens Nielsen blir hedersdoktorer vid Sahlgrenska akademin
”Båda våra hedersdoktorer har ett starkt engagemang i frågor som rör life science, vilket bidragit till att stärka detta område i vår region”, säger Agneta Holmäng, dekan och ordförande vid Sahlgrenska akademins fakultetsstyrelse, om utnämningarna.
-
Study: Our behaviour may have been guided by wishful thinking during the pandemic
A new study suggests that we systematically underestimate health risks if and when it suits us. This was especially true during the pandemic, as our risk assessments may have been guided by wishful thinking rather than a rational perception of the risks.
-
Här visar Astra Zeneca framtidens läkemedelsfabrik
Automatisering är ledordet i framtidens läkemedelsfabrik. I veckan visade Astra Zeneca hur den kan se ut när man slog upp dörren till företagets "Smart Factory Hub" i Södertälje.
-
Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”
“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportunities,” Björn Arvidsson writes in a column.
-
Göran Stiernstedt: “We are the world’s worst at continuity”
Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt does not mind his language when describing the shortcomings of today’s healthcare system. “It makes me extremely frustrated,” he says.
-
Björn Ursing: En ny affärsmodell växer fram för tjänsteföretagen
Tjänsteföretagen inom life science startas ofta med en stor mängd kunskap men med mycket lite kapital, skriver Björn Ursing i en krönika som beskriver nya affärsmodeller för tjänsteföretag i life science-sektorn.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.
-
Now it’s settled: The International Vaccine Institute will be located in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified the agreement, which means that a branch of the institute will be located in Stockholm.
-
Nytt regelverk för diagnostik infört – ”Det börjar synas redan nu att produkter försvinner”
Nu har det nya regelverket för in vitro-diagnostik trätt i kraft. Det påverkar tusentals medicintekniska produkter som används inom sjukvården.
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of exciting results and perhaps a publication in a high-impact journal,” she writes in a column.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
40 miljarder i satsningar i Öresundsregionen – ”En enorm investeringsvåg”
Medicinska företag i Öresundsregionen investerar som aldrig förr, visar en ny rapport.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
New rules for diagnostic products, but who will certify them? “An extreme shortage area”
In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and Covid-19. However, not one single institute in the entire Nordic region is able to certify
BREAKING